Are fluoroquinolones superior antibiotics for the treatment of community-acquired pneumonia?

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Various guidelines for the antibiotic treatment of community-acquired pneumonia (CAP) are presented that include fluoroquinolone antibiotics. The efficacy of current fluoroquinolone antibiotics in the treatment of CAP is summarized. Healthcare resource utilization and shortened duration of clinical symptoms have been shown in some, but not all of CAP trials utilizing fluoroquinolone antibiotics. Although evidence for both the clinical and microbiological efficacy of fluoroquinolone antibiotics is abundant, no convincing data demonstrates that they are superior to other standard antibiotics included in CAP guidelines.

Original languageEnglish (US)
Pages (from-to)317-329
Number of pages13
JournalCurrent Infectious Disease Reports
Volume14
Issue number3
DOIs
StatePublished - Jun 2012

Fingerprint

Fluoroquinolones
Pneumonia
Anti-Bacterial Agents
Guidelines
Delivery of Health Care

Keywords

  • Community-acquired pneumonia
  • Fluorquinolone
  • Levofloxacin
  • Moxifloxacin

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

@article{46d14cec534e42cbb0a4d242b31f2a6f,
title = "Are fluoroquinolones superior antibiotics for the treatment of community-acquired pneumonia?",
abstract = "Various guidelines for the antibiotic treatment of community-acquired pneumonia (CAP) are presented that include fluoroquinolone antibiotics. The efficacy of current fluoroquinolone antibiotics in the treatment of CAP is summarized. Healthcare resource utilization and shortened duration of clinical symptoms have been shown in some, but not all of CAP trials utilizing fluoroquinolone antibiotics. Although evidence for both the clinical and microbiological efficacy of fluoroquinolone antibiotics is abundant, no convincing data demonstrates that they are superior to other standard antibiotics included in CAP guidelines.",
keywords = "Community-acquired pneumonia, Fluorquinolone, Levofloxacin, Moxifloxacin",
author = "Albertson, {Timothy E} and Morrissey, {Brian M} and Andrew Chan",
year = "2012",
month = "6",
doi = "10.1007/s11908-012-0251-y",
language = "English (US)",
volume = "14",
pages = "317--329",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Are fluoroquinolones superior antibiotics for the treatment of community-acquired pneumonia?

AU - Albertson, Timothy E

AU - Morrissey, Brian M

AU - Chan, Andrew

PY - 2012/6

Y1 - 2012/6

N2 - Various guidelines for the antibiotic treatment of community-acquired pneumonia (CAP) are presented that include fluoroquinolone antibiotics. The efficacy of current fluoroquinolone antibiotics in the treatment of CAP is summarized. Healthcare resource utilization and shortened duration of clinical symptoms have been shown in some, but not all of CAP trials utilizing fluoroquinolone antibiotics. Although evidence for both the clinical and microbiological efficacy of fluoroquinolone antibiotics is abundant, no convincing data demonstrates that they are superior to other standard antibiotics included in CAP guidelines.

AB - Various guidelines for the antibiotic treatment of community-acquired pneumonia (CAP) are presented that include fluoroquinolone antibiotics. The efficacy of current fluoroquinolone antibiotics in the treatment of CAP is summarized. Healthcare resource utilization and shortened duration of clinical symptoms have been shown in some, but not all of CAP trials utilizing fluoroquinolone antibiotics. Although evidence for both the clinical and microbiological efficacy of fluoroquinolone antibiotics is abundant, no convincing data demonstrates that they are superior to other standard antibiotics included in CAP guidelines.

KW - Community-acquired pneumonia

KW - Fluorquinolone

KW - Levofloxacin

KW - Moxifloxacin

UR - http://www.scopus.com/inward/record.url?scp=84865626241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865626241&partnerID=8YFLogxK

U2 - 10.1007/s11908-012-0251-y

DO - 10.1007/s11908-012-0251-y

M3 - Article

C2 - 22415582

AN - SCOPUS:84865626241

VL - 14

SP - 317

EP - 329

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 3

ER -